Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alder Biopharmaceuticals
Biotech
Lundbeck pens $2B Alder takeover to boost brain disease pipeline
The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for near-term revenue drivers.
Nick Paul Taylor
Sep 16, 2019 6:17am
Former Insmed CMO Streck resurfaces at Alder
Jan 18, 2019 8:33am
Teva exits chronic cluster headache with phase 3 CGRP drug fade
Jun 15, 2018 11:09am
Chutes & Ladders—Alder poaches Juno executive for CEO
Jun 15, 2018 10:56am
Alder brings on Juno exec as CEO to prep for its migraine launch
Jun 8, 2018 11:20am
Allergan's ubrogepant aces 2nd phase 3 migraine trial
Apr 27, 2018 10:23am
